

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **September 2014**

Commission File Number: **001-36187**

**EVOGENE LTD.**

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street  
Park Rehovot P.O.B 2100  
Rehovot 7612002 Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

\_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

\_\_\_\_\_

## **CONTENTS**

Attached hereto and incorporated by reference herein is the following exhibit:

- 99.1 A Slide Presentation for Investors – September 2014.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.  
(Registrant)

Date: September 15, 2014

By: /s/ Sigal Fattal

---

Sigal Fattal  
Chief Financial Officer

EXHIBIT INDEX

<u>EXHIBIT NO.</u>	<u>DESCRIPTION</u>
99.1	A Slide Presentation for Investors – September 2014.



# Introducing Evogene

September 2014

Ofer Haviv,  
President and CEO

# Safe Harbor Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

# Introducing Evogene

## ► Our mission

Being a world leader in improving plant productivity and performance by harnessing the power of genomics to address the global demand for food, feed and fuel




(1) As of 2010

# World agriculture: the challenge and opportunity


## The challenge: producing more with less

### World population



World population (in billions) | Source: United States Census Bureau.

### Arable land per capita



Hectares per capita, globally | Source: FAO.

## The solution: increasing plant productivity and performance



Seed traits



Seed external

**Opportunity: convergence of biology, computational technology and state-of-the-art agricultural techniques to develop enhanced products**

# Introducing Evogene

## Our mission

Being a world leader in improving plant productivity and performance by harnessing the power of genomics to address the global demand for food, feed and fuel

## ► Our competitive advantage

A unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities, to create, integrate and analyze agriculture related 'big data' for prediction and validation of new products



## Our unique position - solving the industry bottleneck


## Integration and analysis of agriculture related 'big data'



## Costs



# Complexity




## Sources



## Diversity




**Agriculture is becoming heavily digitized creating a tremendous opportunity for innovation-based products**



# Our technology platform

A decade long investment of combining plant science and computational power



# Introducing Evogene

## Our mission

Being a world leader in improving plant productivity and performance by harnessing the power of genomics to address the global demand for food, feed and fuel

## Our competitive advantage

A unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities, to create, integrate and analyze agriculture related 'big data' for prediction and validation of new products


## ► **Target markets & initial product pipeline**

- **Improved seed traits:** biotech seeds (~\$20bn) and conventional seeds (~\$19bn)
- **Novel chemicals and biological applications:** ag-chemicals (~\$54bn) and ag-biologicals (~\$3bn)
- **Advanced seed and farming solutions (Evofuel):** castor as second generation feedstock for biofuels (~\$18bn)<sup>(1)</sup>



(1) As of 2010


# Applying competitive advantage to target markets



Leveraging broadly applicable proprietary technology platform to multiple target markets

# Seed traits - yield & a-biotic stress

Current product program pipeline



Potential near-term catalysts as more genes advance to Phase 2

Note:

Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

# Seed traits - biotic stress

## Current product program pipeline



Crop	Trait	Partner	Discovery	Phase 1	Phase 2	Phase 3	Phase 4
Corn	1. Fusarium	MONSANTO					
	2. Rootworm						
	3. Lygus hesperus	Marrone Bio Innovations					
Soybean	4. Asian Rust	DUPONT					
	5. Nematode	syngenta					
	6. Aphids						
Banana	7. Black Sigatoka	RICOH GREEN INNOVATION					
Cotton	8. Beet Armyworm	Marrone Bio Innovations					



Note:

Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.


# Novel ag-chemicals and ag-biologicals

## Markets and focus




### Ag-chemicals : robust market

- Crossed \$54 billion
- Current focus – herbicides
  - Accounts for 44%
  - Steady increase
  - Strong need for innovation
  - No new “mode of action” discovered in > 20 years



Source: Phillips McDougall, 2013

### Combining biology and chemistry to drive innovation



### Ag-biologicals: rapidly growing market

- Estimated to reach up to \$9 billion in 2020
- Two key segments:
  - Bio-pesticides (~\$2 billion)
    - To reach \$6 billion in 2020
    - Increased focus by industry players
  - Bio-stimulants (~\$1 billion)
    - To reach \$3 billion in 2020
    - Emerging new opportunity

### Short time to product, relatively low development cost



# Seeds (Castor)

Current focus and activities



- Activities begun in 2007
- Established in 2012 as a wholly owned subsidiary
- Full license to all relevant Evogene technologies
- Primary product – castor bean seeds

## Current market: industrial uses

### Short term use

- Existing industries: biopolymers, lubricants, paints, etc.

### The need

- High and volatile castor oil prices

## Strategic market: biodiesel

### Long term use

- Second generation feedstock for biodiesel

### The need

- Cost competitive and scalable feedstock production

## Commercialization of castor varieties expected in 2016

- Key markets: Brazil and Argentina
- >5 million ha. potential for castor large scale production in Brazil
- Downstream strategic partnerships in target markets
  - leading agribusiness, 340,000 ha. in Brazil
  - leading biodiesel producer in Argentina
- Recently signed commercial production agreement with SLC for 2016



Castor field trials, Brazil 2014

# Introducing Evogene

## Our mission

Being a world leader in improving plant productivity and performance by harnessing the power of genomics to address the global demand for food, feed and fuel

## Our competitive advantage


A unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities, to create, integrate and analyze agriculture related 'big data' for prediction and validation of new products

## Improved seed traits


- Improved seed traits: biotech seeds (~\$20bn) and conventional seeds (~\$19bn)
- Novel chemicals and biological applications: ag-chemicals (~\$54bn) and ag-biologicals (~\$3bn)
- Advanced seed and farming solutions(Evofuel): castor as second generation feedstock for biofuels (~\$18bn)

## ➤ Business model & partners

- **Initial revenues:** R&D and milestone payments from partners; castor seed sales
- **Primary long-term revenues:** royalties from seed traits and ag-chemicals/ag-biologicals
- **Collaborations** with five of the world's leading seed



# Our revenue model



<b>D</b> <b>R&amp;D payments</b>	▪ R&D payments paid by partner in the majority of our collaborations
<b>M</b> <b>Milestone fees</b>	▪ Additional payments received upon achieving predetermined objectives
<b>R</b> <b>Royalties</b>	▪ Potential royalties vary on average between 5%-12% of future trait sales

## Seeds - Evofuel

 <b>Evofuel</b>	▪ Revenue from direct castor bean seed sales anticipated from 2016 onwards
--	--

# Partnerships with world leading seed companies



- >10 collaboration agreements
- Patent portfolio covers c.4000 genes
- Portfolio of 25 product programs across various crops and traits
- 100s of genes being developed in partners' pipelines
- Most advanced genes in Phase 2

(1) Source: Phillips McDougall.

(2) Limagrain is the controlling shareholder of Vilmorin & Cie, a global leading seed manufacturer. Limagrain is also the sole owner of Biogemma, with which Evogene has an existing collaboration.

# Introducing Evogene

**Our mission**

Being a world leader in improving plant productivity and performance by harnessing the power of genomics to address the global demand for food, feed and fuel

**Our competitive advantage**

A unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities, to create, integrate and analyze agriculture related 'big data' for prediction and validation of new products

**Improved seed traits**

- Improved seed traits: biotech seeds (c.\$20bn) and conventional seeds (c.\$19bn)
- Seed external - novel chemicals and biological applications: ag-chemicals (c.\$54bn) and ag-biologicals (c.\$3bn)
- Advanced seed and farming solutions (wholly owned subsidiary – Evofuel): castor as second generation feedstock for biofuels (c.\$18bn)(1)

**Business model & partners**

- Initial revenues: R&D and milestone payments from partners; castor seed sales
- Primary long-term revenues: royalties from seed traits and ag-chemicals/ag biologicals
- Collaborations with five of the world's leading seed companies

**Financial information**

- Corporate identity
- Cash status
- Current revenues and R&D costs



# Financial information

## ■ Corporate Identity


- Key milestones:
  - 2002 - spins off from Compugen (NASDAQ:CGN)
  - 2007 – lists on TASE (EVGN) **~\$34m** (gross proceeds)
  - 2013 – lists on NYSE (EVGN) **~\$85m** (gross proceeds)
- Market cap<sup>(1)</sup> **~\$320m**, **~25m** shares outstanding
- **203 FTEs**, 82% R&D positions

## ■ Cash Position (June 30, 2014)

- **~\$120m** in cash, short and long term bank deposits and marketable securities
- No long-term debt


## ■ Revenues and Total R&D Costs

- **\$17.6m** in Total Revenues in FY13, **\$3.8m** in 2Q14, comprising mostly R&D payments



- **\$21.2m** Total R&D Costs in FY13, **\$5.8m** in 2Q14, comprising:

- Support of collaborations
- Independent R&D expenses



(1) As of 12 September, 2014



# Thank You!